Aussie researchers trial new technology to help seniors stay on their feet

Researchers at the University of Queensland are trialling new technology to help senior Australians stay on their feet and reduce falls. 

The VertiGuard is a light-weight sensor worn on a belt that continuously records and detects the body’s sway in different directions.

An exercise program is created using the data, which helps train the body into better movement and balance.

READ MORE: Seniors swarming the internet to exercise, stay in touch in lockdown



a person standing in front of a computer: David Ramsay is taking part in the trial after recently suffering a fall.


© Nine
David Ramsay is taking part in the trial after recently suffering a fall.



a table with a remote control: The VertiGuard is a light-weight sensor worn on a belt that continuously records and detects the body's sway in different directions.


© Nine
The VertiGuard is a light-weight sensor worn on a belt that continuously records and detects the body’s sway in different directions.

David Ramsay is taking part in the trial after recently suffering a fall.

“I do have a bit of an issue with balance,” he said.

“If I can improve the way I walk and my posture when I’m walking

Read More

Unilever to Trial Four-Day Working Week in New Zealand

(Bloomberg) — Consumer goods giant Unilever will trial a four-day working week in New Zealand to enhance worker wellbeing and boost productivity.



a close up of a sign: The Unilever NV logo sits on a a jar of Marmite, manufactured by Unilever NV, in this arranged photograph in London, U.K., on Tuesday, Feb. 21, 2017. On Sunday, Kraft Heinz Co. withdrew its bid for Unilever, which would've created the world's No. 2 food-and-beverage company.


© Bloomberg
The Unilever NV logo sits on a a jar of Marmite, manufactured by Unilever NV, in this arranged photograph in London, U.K., on Tuesday, Feb. 21, 2017. On Sunday, Kraft Heinz Co. withdrew its bid for Unilever, which would’ve created the world’s No. 2 food-and-beverage company.

All 81 workers will be eligible to work for four days on full pay, New Zealand Managing Director Nick Bangs said in a statement Tuesday. Most of the staff are based at Unilever’s Auckland headquarters and distribution center after the company closed manufacturing operations in 2015.

“The old days of working are outdated and no longer fit for purpose,” said Bangs. “Our goal is to measure performance on output, not time.”

The trial, which starts this month and will run

Read More

AnaptysBio: Imsidolimab Q4 FDA Meeting, Dostarlimab Q4 2020 Approval, And New Trial Initiations, 61% Upside (NASDAQ:ANAB)

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The companyGraphic Source: AnaptysBio, Inc.

Introduction: What is AnaptysBio?

AnaptysBio (NASDAQ: ANAB) is a $675M mid-clinical-stage biotechnology company focused on developing immunology therapeutics based around emerging immune control mechanisms applicable to inflammation and immuno-oncology. AnaptysBio develops principally antibody therapeutics based on their claimed-expertise in somatic hypermutation, in vitro tailored antibody generated from B-cells.

Founded in 2005 and based in California, AnaptysBio has since developed several great partnerships including with GlaxoSmithKline (GSK) and Bristol-Myers Squibb (BMY) generating $8M in 2019 revenues, $15M in 9M 2020 on top of $374.5M in cash and equivalents allowing operational funding through at least into 2023.

Products/Pipeline: AnaptysBio is developing 7 clinical-stage therapeutics with 4 from their pipeline being wholly-owned target programs, Imsidolimab (Phase 2), Etokimab (Phase 2), ANB030 (Phase 1), and ANB032 (“IND”), focused on modulating therapeutic targets genetically associated with inflammatory disorders. AnaptysBio is developing 4 therapeutics for GSK and 2 for BMY. AnaptysBio is

Read More

At 12.6% CAGR, Clinical Trial Management System Market Size | Global Industry Analysis and Opportunity Assessment 2020-2025

The MarketWatch News Department was not involved in the creation of this content.

Nov 29, 2020 (Heraldkeepers) —
Clinical Trial Management System Market is valued at USD 662.4 Million in 2019 and expected to reach USD 1520.3 Million by 2026 with the CAGR of 12.6% over the forecast period.

Global Clinical Trial Management System Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2020-2026- Increasing R&D investment by the pharmaceutical, life science, and clinical research industries is one of the major factors driving the growth of Global Clinical Trial Management System Market

Get Sample of This [email protected]https://brandessenceresearch.com/requestSample/PostId/1351

Scope of Global Clinical Trial Management System Market-

It is a software system used by biotechnological and pharmaceutical industries to manage clinical trials in clinical research. It involves management of clinical trial records in clinical research. It starts from planning of research proposal to preparation, conduct of trial, report generation, CTMS maintenance

Read More

Mastercard expands digital ID trial with Deakin and Australia Post

mastercard-deakin-australia-post.jpg

Image: Mastercard

Mastercard announced the quiet expansion of the trial for its digital identification service, following the successful completion of phase one with partners Deakin University and Australia Post.

Announced in December, the three parties kicked off two trials: The first for an identity verification process of student registration and digital exams at Deakin’s Burwood and Geelong campuses in Victoria, and the second integrating Mastercard’s digital ID solution with the one the postal service is working on.

See also: Australia Post a ‘trusted’ service provider for government identification

The pilot saw students create a digital identity in Australia Post’s Digital ID app and use it to gain access to Deakin University’s exam portal. Mastercard said the ID successfully orchestrated the sharing of verified identity data between the two parties, sending only the specific personal information required to permit entry using its network.

The three organisations expanded the trial to verify

Read More

Australia and Singapore to Trial ‘Paperless’ Trade Using Blockchain Technology

The Australian Border Force (ABF), the country’s customs and border protection agency, wants to simplify cross-border trade with Singapore using blockchain technology.

Under the Australia-Singapore Digital Economy Agreement (DEA), a blockchain trial was launched this week in an attempt to make it easier for businesses to digitally exchange trade documentation, per an ABF announcement on Wednesday.

In collaboration with Singapore Customs and the Singapore Infocomm Media Development Authority (IMDA), the blockchain trial aims to reduce administration costs and increase trade efficiency. Specifically, it will test digital verification platforms across both the ABF’s intergovernmental ledger and IMDA’s TradeTrust platform for sharing electronic documents, primarily certificates of origin.

Related: Australian Investment Group With Billions in AUM Starts Investing in Bitcoin Futures

“This initiative will incorporate paperless trading and secure digital exchange of trade information as part of the future architecture and design of an Australian Trade Single Window,” said ABF Commissioner Michael

Read More

Greenwich LifeSciences Announces Second Publication and Second Poster Presentation of Phase III Clinical Trial of Potential Breakthrough Technology for Recurring Breast Cancer

STAFFORD, Texas–(BUSINESS WIRE)–Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the publication of a second abstract at the San Antonio Breast Cancer Symposium (SABCS), jointly authored by Professor Mothaffar F. Rimawi, the Global Principal Investigator of the GP2 Phase III clinical trial, and the Executive Medical Director and Co-Leader of the Breast Cancer Program at the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, and Professor C. Kent Osborne, Tina and Dudley Sharp Chair in Oncology and the founding Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine. The abstract will be displayed as the Company’s second poster on Wednesday, December 9, 2020 in a virtual format with an introductory audio track.

The abstract highlights

Read More

Clinical trial reverses two biological processes associated with aging in human cells — ScienceDaily

A new study from Tel Aviv University (TAU) and the Shamir Medical Center in Israel indicates that hyperbaric oxygen treatments (HBOT) in healthy aging adults can stop the aging of blood cells and reverse the aging process. In the biological sense, the adults’ blood cells actually grow younger as the treatments progress.

The researchers found that a unique protocol of treatments with high-pressure oxygen in a pressure chamber can reverse two major processes associated with aging and its illnesses: the shortening of telomeres (protective regions located at both ends of every chromosome) and the accumulation of old and malfunctioning cells in the body. Focusing on immune cells containing DNA obtained from the participants’ blood, the study discovered a lengthening of up to 38% of the telomeres, as well as a decrease of up to 37% in the presence of senescent cells.

The study was led by Professor Shai Efrati of

Read More

Blind man, ‘born to run,’ completes solo marathon with trial app to guide him

NEW YORK (Reuters) – A blind man completed a 5-kilometer (3.1-mile) run in New York’s Central Park without a guide dog or human help this week. His navigation aid? Artificial intelligence through headphones plugged into a smartphone.

“The safest thing for a blind man is to sit still. I ain’t sitting still,” said Thomas Panek, 50, who lost his vision in his early 20s due to a genetic condition and runs Guiding Eyes for the Blind, a guide dog school.

The marathon enthusiast got tired of having to follow slower runners as a guide. So he decided a year ago to find a way to run solo.

He turned to Google to find a way for a phone to “tell me where to go,” said Panek, who believes “humans are born to run.”

He worked with the Alphabet Inc unit to create a research program. A smartphone camera picks up

Read More